L W Hoyer|M E Rick - JoVE Visualize

Showing results (71-80 of 120) with videos related to

Pageof 12

Sort By:

JAMA|February 22, 1985

Benefits of danazol treatment in patients with hemophilia A (classic hemophilia)H R Gralnick, P Maisonneuve, Y Sultan, et al.

Genomics|February 1, 1993

Spectrum of mutations in CRM-positive and CRM-reduced hemophilia AM J McGinniss, H H Kazazian, L W Hoyer, et al.

British Journal of Haematology|November 1, 1983

Von Willebrand factor multimer patterns in von Willebrand's diseaseL W Hoyer, C R Rizza, E G Tuddenham, et al.

Blood|February 1, 1988

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitorsC W McMillan, S S Shapiro, D Whitehurst, et al.

Blood|July 1, 1986

DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding timesG E Marti, M E Rick, J Sidbury, et al.

The Journal of Laboratory and Clinical Medicine|March 1, 1989

Subendothelial matrix of cultured endothelial cells contains fully processed high molecular weight von Willebrand factorS H Tannenbaum, M E Rick, B Shafer, et al.

Proceedings of the National Academy of Sciences of the United States of America|June 11, 1992

Hemophilia A due to mutations that create new N-glycosylation sitesA M Aly, M Higuchi, C K Kasper, et al.

Genomics|January 1, 1988

Mild hemophilia A associated with a cryptic donor splice site mutation in intron 4 of the factor VIII geneH Youssoufian, H H Kazazian, A Patel, et al.

The American Journal of Medicine|October 1, 1978

Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapyG R Mundy, M E Rick, R Turcotte, et al.

Proceedings of the National Academy of Sciences of the United States of America|June 1, 1989

Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine)M Arai, H Inaba, M Higuchi, et al.

Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:

Pageof 12

JAMA|February 22, 1985

Benefits of danazol treatment in patients with hemophilia A (classic hemophilia)H R Gralnick, P Maisonneuve, Y Sultan, et al.

Genomics|February 1, 1993

Spectrum of mutations in CRM-positive and CRM-reduced hemophilia AM J McGinniss, H H Kazazian, L W Hoyer, et al.

British Journal of Haematology|November 1, 1983

Von Willebrand factor multimer patterns in von Willebrand's diseaseL W Hoyer, C R Rizza, E G Tuddenham, et al.

Blood|February 1, 1988

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitorsC W McMillan, S S Shapiro, D Whitehurst, et al.

Blood|July 1, 1986

DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding timesG E Marti, M E Rick, J Sidbury, et al.

The Journal of Laboratory and Clinical Medicine|March 1, 1989

Subendothelial matrix of cultured endothelial cells contains fully processed high molecular weight von Willebrand factorS H Tannenbaum, M E Rick, B Shafer, et al.

Proceedings of the National Academy of Sciences of the United States of America|June 11, 1992

Hemophilia A due to mutations that create new N-glycosylation sitesA M Aly, M Higuchi, C K Kasper, et al.

Genomics|January 1, 1988

Mild hemophilia A associated with a cryptic donor splice site mutation in intron 4 of the factor VIII geneH Youssoufian, H H Kazazian, A Patel, et al.

The American Journal of Medicine|October 1, 1978

Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapyG R Mundy, M E Rick, R Turcotte, et al.

Proceedings of the National Academy of Sciences of the United States of America|June 1, 1989

Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine)M Arai, H Inaba, M Higuchi, et al.

Pageof 12